{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:30:51Z","timestamp":1785439851077,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Innovation Project of Fujian Provincial Health Commission","award":["2022CXB015"],"award-info":[{"award-number":["2022CXB015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>S100A12 acts as a pro-inflammatory agent in vivo, with a close relationship with plaque formation in patients with acute coronary syndrome (ACS), end-stage renal disease, and diabetes. Peripheral arterial disease (PAD) can lead to mobility difficulties and ultimately disability and amputation. The association between S100A12 and risk of peripheral arterial disease remains unclear. This study aims to investigate the association between S100A12 and the risk of PAD in patients with dyslipidemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From March 2023 to June 2024, 478 patients were included in this cross-sectional study. They were divided into PAD group (<jats:italic>n<\/jats:italic>\u2009=\u2009105) and control group (<jats:italic>n<\/jats:italic>\u2009=\u2009373) according to the presence or absence of PAD (The diagnosis of PAD is a combination of the patient\u2019s clinical symptoms, imaging evidence and ankle-brachial index). Plasma S100A12 was detected by available kit. General information, disease history, smoking history, and laboratory indicators were collected from both groups. The relationship between S100A12 and the risk of PAD was analyzed using statistical methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Levels of S100A12 were significantly higher in the PAD group of dyslipidemia [0.22 (0.13,1.49) ng\/cL vs. 0.13 (0.10,0.18)ng\/cL, <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.001]. Univariate and multivariate logistic regression analyses suggested that the risk of PAD was significantly higher with increasing levels of S100A12 [Odd ratio (OR) (95%CI)\u2009=\u20092.264 (1.681, 3.047), <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.05]. In addition, lower high-density lipoprotein cholesterol (HDL-C) level and diabetes mellitus (DM) were independent risk factors for PAD [OR (95%CI)\u2009=\u20090.388 (0.186,0.809), <jats:italic>p<\/jats:italic> value\u2009=\u20090.012; OR\u2009=\u20092.375 (1.527,3.695), <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.001]. Subgroup analysis suggested that S100A12 was significantly and positively associated with the risk of PAD in all subgroups, regardless of whether HDL-C levels\u2009&lt;\u20091.03 mmol\/L, age\u2009&gt;\u200960 years, and presence of diabetes or hypertension. Restricted cubic spline (RCS) curves suggested that the correlation between S100A12 and the risk of PAD was nonlinear (<jats:italic>p<\/jats:italic>-non-linear value\u2009&lt;\u20090.05). The RCS curves showed that the positive correlation between S100A12 and the risk of PAD was stronger when the S100A12 level was less than 1.00ng\/cL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In conclusion, elevated S100A12 level is an independent risk factor for PAD in patients with dyslipidemia. In different subgroups, S100A12 was significantly and positively associated with the risk of PAD after adjusting for different factors. There is a non-linear relationship between S100A12 and the risk of PAD, with a stronger positive correlation at S100A12 levels below 1.00ng\/cL. These findings implied that S100A12 is a potential biomarker for identifying patients with dyslipidemia who are at high risk of developing PAD. They also implied that S100A12 levels can be routinely monitored in dyslipidemic populations for the early detection of PAD and to guide the management of PAD. Finally, the results of this study emphasize that inflammation in dyslipidemia patients plays an important role in the development of PAD, suggesting that lipid control and immunomodulation may be effective in the prevention of PAD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>MR-35-24-038431.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12872-025-04752-2","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:54:46Z","timestamp":1745459686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between S100A12 and risk of peripheral arterial disease in patients with dyslipidemia: a cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Wenyu","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"4752_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.amjcard.2024.03.002","volume":"218","author":"Y You","year":"2024","unstructured":"You Y, Zeng N, Wu W, et al. Association of serum homocysteine with peripheral arterial disease in patients without diabetes: A study based on National health and nutrition examination survey database. Am J Cardiol. 2024;218:16\u201323.","journal-title":"Am J Cardiol"},{"issue":"36","key":"4752_CR2","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u2013700.","journal-title":"Eur Heart J"},{"key":"4752_CR3","doi-asserted-by":"crossref","unstructured":"Gornik HL, Aronow HD, Goodney PP, et al. ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313\u2013410.","DOI":"10.1161\/CIR.0000000000001251"},{"issue":"8","key":"4752_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.medcli.2023.06.005","volume":"161","author":"D Mandaglio-Collados","year":"2023","unstructured":"Mandaglio-Collados D, Mar\u00edn F, Rivera-Caravaca JM. Peripheral artery disease: update on etiology, pathophysiology, diagnosis and treatment. Med Clin (Barc). 2023;161(8):344\u201350.","journal-title":"Med Clin (Barc)"},{"issue":"10","key":"4752_CR5","doi-asserted-by":"publisher","first-page":"e1553","DOI":"10.1016\/S2214-109X(23)00355-8","volume":"11","author":"GBD 2019 Peripheral Artery Disease Collaborators","year":"2023","unstructured":"GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Glob Health. 2023;11(10):e1553\u201365.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"4752_CR6","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3390\/diagnostics12102499","volume":"12","author":"V Aursulesei Onofrei","year":"2022","unstructured":"Aursulesei Onofrei V, Ceasovschih A, Marcu DTM, et al. Mortality risk assessment in peripheral arterial Disease-The burden of cardiovascular risk factors over the years: A single center\u2019s experience. Diagnostics (Basel). 2022;12(10):2499.","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 1","key":"4752_CR7","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.ihj.2024.01.010","volume":"76","author":"A Yadav","year":"2024","unstructured":"Yadav A, Sawant V, Singh Bedi V, et al. Dyslipidemia and peripheral arterial disease. Indian Heart J. 2024;76(Suppl 1):S86\u20139. https:\/\/doi.org\/10.1016\/j.ihj.2024.01.010. Epub 2024 Jan 13.","journal-title":"Indian Heart J"},{"key":"4752_CR8","doi-asserted-by":"crossref","unstructured":"Tao M, Zhang Y, Li Q et al. Association of lipids and lipid-lowering drugs with peripheral arterial disease: A Mendelian randomization study. J Clin Lipidol. 2024,18(6):e968-e976.","DOI":"10.1016\/j.jacl.2024.06.007"},{"issue":"2","key":"4752_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/clp.12.6","volume":"7","author":"AW Pollak","year":"2012","unstructured":"Pollak AW, Kramer CM. LDL Lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality? Clin Lipidol. 2012;7(2):141\u20139.","journal-title":"Clin Lipidol"},{"key":"4752_CR10","doi-asserted-by":"crossref","unstructured":"Gallo A, Le Goff W, Santos RD et al. Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors. Eur J Clin Invest. 2024 Oct 6:e14326.","DOI":"10.1111\/eci.14326"},{"issue":"12","key":"4752_CR11","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1161\/ATVBAHA.115.302072","volume":"35","author":"A Oesterle","year":"2015","unstructured":"Oesterle A, Bowman MA. S100A12 and the S100\/Calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets. Arterioscler Thromb Vasc Biol. 2015;35(12):2496\u2013507.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"4752_CR12","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1210\/jc.2005-2559","volume":"91","author":"G Basta","year":"2006","unstructured":"Basta G, Sironi AM, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006;91(11):4628\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"4752_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jcjd.2021.01.004","volume":"45","author":"X Wang","year":"2021","unstructured":"Wang X, Wang Q, Wei D, et al. Association between soluble receptor for advanced glycation end product and endogenous secretory soluble receptor for advanced glycation end product levels and carotid atherosclerosis in diabetes: A systematic review and Meta-Analysis. Can J Diabetes. 2021;45(7):634\u201340.","journal-title":"Can J Diabetes"},{"key":"4752_CR14","first-page":"907078","volume":"2012","author":"B Meijer","year":"2012","unstructured":"Meijer B, Gearry RB, Day AS. The role of S100A12 as a systemic marker of inflammation. Int J Inflam. 2012;2012:907078.","journal-title":"Int J Inflam"},{"key":"4752_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cca.2019.11.019","volume":"502","author":"X Xiao","year":"2020","unstructured":"Xiao X, Yang C, Qu SL, et al. S100 proteins in atherosclerosis. Clin Chim Acta. 2020;502:293\u2013304.","journal-title":"Clin Chim Acta"},{"key":"4752_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-015-0257-5","volume":"14","author":"J Malmstedt","year":"2015","unstructured":"Malmstedt J, K\u00e4rvestedt L, Swedenborg J, et al. The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study. Cardiovasc Diabetol. 2015;14:93.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"4752_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000335198","volume":"1","author":"Y Shiotsu","year":"2011","unstructured":"Shiotsu Y, Mori Y, Hatta T, et al. Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease. Nephron Extra. 2011;1(1):242\u201350.","journal-title":"Nephron Extra"},{"issue":"3","key":"4752_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/bmm-2016-0253","volume":"11","author":"Z Buyukterzi","year":"2017","unstructured":"Buyukterzi Z, Can U, Alpaydin S, et al. Enhanced S100A9 and S100A12 expression in acute coronary syndrome. Biomark Med. 2017;11(3):229\u201337.","journal-title":"Biomark Med"},{"key":"4752_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijcard.2023.02.005","volume":"376","author":"G Tsirebolos","year":"2023","unstructured":"Tsirebolos G, Tsoporis JN, Drosatos IA, et al. Emerging markers of inflammation and oxidative stress as potential predictors of coronary artery disease. Int J Cardiol. 2023;376:127\u201333.","journal-title":"Int J Cardiol"},{"issue":"3","key":"4752_CR20","first-page":"221","volume":"51","author":"Joint Committee on the Chinese Guidelines for Lipid Management","year":"2023","unstructured":"Joint Committee on the Chinese Guidelines for Lipid Management. [Chinese guidelines for lipid management (2023)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023;51(3):221\u201355.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"21","key":"4752_CR21","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994\u20132004.","journal-title":"N Engl J Med"},{"key":"4752_CR22","doi-asserted-by":"publisher","first-page":"747511","DOI":"10.3389\/fcvm.2021.747511","volume":"8","author":"X Zhang","year":"2021","unstructured":"Zhang X, Cheng M, Gao N, et al. Utility of S100A12 as an early biomarker in patients with ST-Segment elevation myocardial infarction. Front Cardiovasc Med. 2021;8:747511.","journal-title":"Front Cardiovasc Med"},{"key":"4752_CR23","doi-asserted-by":"publisher","first-page":"874436","DOI":"10.3389\/fcvm.2022.874436","volume":"9","author":"H Zhai","year":"2022","unstructured":"Zhai H, Huang L, Gong Y, et al. Human plasma transcriptome implicates dysregulated S100A12 expression: A strong, Early-Stage prognostic factor in ST-Segment elevated myocardial infarction: bioinformatics analysis and experimental verification. Front Cardiovasc Med. 2022;9:874436.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"4752_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3892\/etm.2020.8721","volume":"20","author":"H Liang","year":"2020","unstructured":"Liang H, Cui Y, Bu H, et al. Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation. Exp Ther Med. 2020;20(1):211\u20138.","journal-title":"Exp Ther Med"},{"key":"4752_CR25","doi-asserted-by":"publisher","first-page":"896645","DOI":"10.3389\/fimmu.2022.896645","volume":"13","author":"Z Yao","year":"2022","unstructured":"Yao Z, Zhang B, Niu G, et al. Neutrophil infiltration characterized by upregulation of S100A8, S100A9, S100A12 and CXCR2 is associated with the Co-Occurrence of Crohn\u2019s disease and peripheral artery disease. Front Immunol. 2022;13:896645.","journal-title":"Front Immunol"},{"key":"4752_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","volume":"97","author":"MA Hofmann","year":"1999","unstructured":"Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel Proinflammatory axis: a central cell surface receptor for S100\/calgranulin polypeptides. Cell. 1999;97:889\u2013901.","journal-title":"Cell"},{"issue":"3","key":"4752_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/jcb.22575","volume":"110","author":"G Srikrishna","year":"2010","unstructured":"Srikrishna G, Nayak J, Weigle B, et al. Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem. 2010;110(3):645\u201359.","journal-title":"J Cell Biochem"},{"issue":"12","key":"4752_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00109-013-1091-4","volume":"91","author":"HJ Tae","year":"2013","unstructured":"Tae HJ, Kim JM, Park S, et al. The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. J Mol Med. 2013;91(12):1369\u201381.","journal-title":"J Mol Med"},{"issue":"5","key":"4752_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.5551\/jat.61630","volume":"29","author":"T Komatsu","year":"2022","unstructured":"Komatsu T, Ayaori M, Uto-Kondo H, et al. Atorvastatin reduces Circulating S100A12 levels in patients with carotid atherosclerotic plaques - A link with plaque inflammation. J Atheroscler Thromb. 2022;29(5):775\u201384.","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"4752_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/CIRCULATIONAHA.118.039262","volume":"140","author":"Y Li","year":"2019","unstructured":"Li Y, Chen B, Yang X, et al. S100a8\/a9 signaling causes mitochondrial dysfunction and cardiomyocyte death in response to ischemic\/reperfusion injury. Circulation. 2019;140(9):751\u201364.","journal-title":"Circulation"},{"issue":"3","key":"4752_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1189\/jlb.0706433","volume":"81","author":"HY Sroussi","year":"2007","unstructured":"Sroussi HY, Berline J, Palefsky JM. Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro. J Leukoc Biol. 2007;81(3):818\u201324.","journal-title":"J Leukoc Biol"},{"key":"4752_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1189\/jlb.1008608","volume":"86","author":"SY Lim","year":"2009","unstructured":"Lim SY, Raftery MJ, Goyette J, et al. Oxidative modifications of S100 proteins: functional regulation by redox. J Leukoc Biol. 2009;86:577\u201387.","journal-title":"J Leukoc Biol"},{"key":"4752_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijcard.2020.09.004","volume":"322","author":"\u017d Reiner","year":"2021","unstructured":"Reiner \u017d, De Sutter J, Ryden L, et al. Peripheral arterial disease and intermittent claudication in coronary heart disease patients. Int J Cardiol. 2021;322:227\u201332.","journal-title":"Int J Cardiol"},{"issue":"4","key":"4752_CR34","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIR.0000000000001192","volume":"149","author":"KA Gallagher","year":"2024","unstructured":"Gallagher KA, Mills JL, Armstrong DG, et al. Current status and principles for the treatment and prevention of diabetic foot ulcers in the cardiovascular patient population: A scientific statement from the American heart association. Circulation. 2024;149(4):e232\u201353.","journal-title":"Circulation"},{"issue":"5","key":"4752_CR35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"A Poznyak","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, et al. The diabetes Mellitus-Atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4752_CR36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/jpm14090996","volume":"14","author":"C Madaudo","year":"2024","unstructured":"Madaudo C, Bono G, Ortello A, et al. Dysfunctional High-Density lipoprotein cholesterol and coronary artery disease: A narrative review. J Pers Med. 2024;14(9):996.","journal-title":"J Pers Med"},{"issue":"11","key":"4752_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/CIRCRESAHA.123.321563","volume":"132","author":"MF Linton","year":"2023","unstructured":"Linton MF, Yancey PG, Tao H, et al. HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy. Circ Res. 2023;132(11):1521\u201345.","journal-title":"Circ Res"},{"key":"4752_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/cvr\/cvu139","volume":"103","author":"A Kratzer","year":"2014","unstructured":"Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res. 2014;103:350\u201361.","journal-title":"Cardiovasc Res"},{"key":"4752_CR39","doi-asserted-by":"publisher","first-page":"e47286","DOI":"10.1371\/journal.pone.0047286","volume":"7","author":"Y Feng","year":"2012","unstructured":"Feng Y, Schouteden S, Geenens R, et al. Hematopoietic stem\/progenitor cell proliferation and differentiation is differentially regulated by high-density and low-density lipoproteins in mice. PLoS ONE. 2012;7:e47286.","journal-title":"PLoS ONE"},{"key":"4752_CR40","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1161\/ATVBAHA.114.304006","volume":"34","author":"M Gao","year":"2014","unstructured":"Gao M, Zhao D, Schouteden S, et al. Regulation of high-density lipoprotein on hematopoietic stem\/progenitor cells in atherosclerosis requires scavenger receptor type BI expression. Arterioscler Thromb Vasc Biol. 2014;34:1900\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4752_CR41","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.108.793869","volume":"118","author":"L Yvan-Charvet","year":"2008","unstructured":"Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118:1837\u201347.","journal-title":"Circulation"},{"key":"4752_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ni.2784","volume":"15","author":"D De Nardo","year":"2014","unstructured":"De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014;15:152\u201360.","journal-title":"Nat Immunol"},{"key":"4752_CR43","doi-asserted-by":"publisher","first-page":"e22274","DOI":"10.1096\/fj.201800810R","volume":"36","author":"M Darabi","year":"2022","unstructured":"Darabi M, Lhomme M, Dahik VD, et al. Phosphatidylserine enhances anti-inflammatory effects of reconstituted HDL in macrophages via distinct intracellular pathways. FASEB J. 2022;36:e22274.","journal-title":"FASEB J"},{"key":"4752_CR44","doi-asserted-by":"publisher","first-page":"1324890","DOI":"10.3389\/fimmu.2024.1324890","volume":"15","author":"M Ma","year":"2024","unstructured":"Ma M, Wu K, Sun T, et al. Impacts of systemic inflammation response index on the prognosis of patients with ischemic heart failure after percutaneous coronary intervention. Front Immunol. 2024;15:1324890.","journal-title":"Front Immunol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04752-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:54:48Z","timestamp":1745459688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04752-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4752"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04752-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors are accountable for all aspects of the work and ensure that the accuracy- or integrity-related issues are properly researched and addressed. This study is in accordance with the 2013 revision of the Declaration of Helsinki. The Ethics Committee of Shanghai Sixth People\u2019s Hospital Fujian approved this study (jjsyyyxll-2022030). Written informed consent was obtained from all participants, and the consent form template was approved by the Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}